Clinical Trial Update: Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis [Phase 3]

View source ↗

Summary

Ongoing Phase 3 trial evaluating ravulizumab in pediatric participants with generalized myasthenia gravis, assessing pharmacokinetics, pharmacodynamics, efficac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Myasthenia Gravis

Drugs mentioned

• Ravulizumab (ravulizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Generalized Myasthenia Gravis, gMG | Phase 3 | Status: ACTIVE_NOT_RECRUITING